Federal Register of Legislation - Australian Government

Primary content

PB 81 of 2019 Determinations/Health as made
This instrument amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010) to add two drugs to F1 and move two currently listed drugs from F1 to F2 in addition to changing the drug description for two drugs on F2 in line with the main listing instrument. It also removes one drug that is delisting off the Pharmaceutical Benefits Scheme (PBS) and is required to be removed from F1.
Administered by: Health
Registered 30 Sep 2019
Tabling HistoryDate
Tabled HR14-Oct-2019
Tabled Senate14-Oct-2019
To be repealed 06 Dec 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

 

PB 81 of 2019

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated              30 September 2019

 

 

 

 

 

 

 

 

 

THEA DANIEL

 

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

Part 1         Preliminary

1              Name of Determination

         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 9).

         (2)   This Determination may also be cited as PB 81 of 2019.

2              Commencement

                This Determination commences on 1 October 2019.

3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).


Schedule 1             Amendments

 

(Section 3)

 

[1]     Schedule 1, after item dealing with Apraclonidine

 

Insert

Aprepitant

 

[2]     Schedule 1, after item dealing with Bevacizumab

 

Omit

Biperiden

 

[3]     Schedule 1, after item dealing with Insulin detemir

 

Omit

Insulin glargine

 

[4]     Schedule 1, after item dealing with Ritonavir

 

Omit

Rituximab

 

[5]     Schedule 1, after item dealing with Tapentadol

 

Insert

Teduglutide

 

[6]     Schedule 2, after item dealing with Flutamide

 

Omit

Fluticasone

Fluticasone with Salmeterol

Insert

Fluticasone propionate

Fluticasone propionate with salmeterol

 

[7]     Schedule 2, after item dealing with Infliximab

 

Insert

Insulin glargine

 

[8]     Schedule 2, after item dealing with Risperidone

 

Insert

Rituximab